§ 13F · FUND PROFILE
ORBIMED ADVISORS LLC.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · — (13F)Positions · 114Turnover · — · Q1Filed · May 15, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$1.0B deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q1 2026
FILED MAY 15, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q1 |
|---|---|---|---|---|---|---|
| 1 | EWTX | EDGEWISE THERAPEUTICS INC | 15.52M | $489M | 9.7% | ±0% |
| 2 | ELVN | ENLIVEN THERAPEUTICS INC | 7.96M | $312M | 6.2% | ±0% |
| 3 | MDXH | MDXHEALTH SA | 124.31M | $286M | 5.7% | NEW |
| 4 | LLY | ELI LILLY & CO | 237K | $218M | 4.3% | −21% |
| 5 | SVA | SINOVAC BIOTECH LTD | 2.72M | $184M | 3.7% | ±0% |
| 6 | RCEL | AVITA MEDICAL INC | 40.97M | $154M | 3.1% | NEW |
| 7 | BSX | BOSTON SCIENTIFIC CORP | 2.38M | $149M | 3.0% | −2% |
| 8 | SION | SIONNA THERAPEUTICS INC | 3.53M | $142M | 2.8% | −1% |
| 9 | AZN | ASTRAZENECA PLC | 670K | $132M | 2.6% | NEW |
| 10 | MYGN | MYRIAD GENETICS INC | 125.00M | $123M | 2.4% | NEW |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE ORBIMED SIGNAL
AC read
ORBIMED ADVISORS LLC is classified as a Other fund.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
1 FILINGS
Q1 2026
Steady book
+0 buys · −0 exits · 0 changed
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed